News

News Subscription

Nov 19. 2014
Basilea's oncology drug candidate BAL101553 induces significant anti-tumor effect in treatment-refractory tumor models
Read more
Download
Nov 03. 2014
Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis
Read more
Download
Oct 16. 2014
Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study
Read more
Download
Oct 09. 2014
Basilea reports that further subgroup and health economic analyses of isavuconazole phase 3 studies will be presented at IDWeek conference
Read more
Download
Sep 06. 2014
Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis
Read more
Download
Sep 05. 2014
Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC
Read more
Download
Aug 21. 2014
European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review
Read more
Download
Aug 18. 2014
Basilea appoints Chief Commercial Officer
Read more
Download
Aug 14. 2014
Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014
Read more
Download
Jul 21. 2014
Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider
Read more
Download